Related Experiment Videos
Cell cycle effects of thaliblastine
F Seifert1, D K Todorov, K J Hutter
1German Cancer Research Center, Heidelberg, Germany.
Journal of Cancer Research and Clinical Oncology
|January 1, 1996
Summary
Thaliblastine, an antitumor alkaloid, halts ovarian cancer cell cycles. It causes a G2/M block initially, followed by G1 arrest in both sensitive and cisplatin-resistant O-342 cells.
Area of Science:
- Pharmacology
- Cancer Biology
- Cell Cycle Analysis
Background:
- Thaliblastine is a non-myelotoxic antitumor drug with a unique dimeric aporphine benzylisoquinoline alkaloid structure.
- It exhibits antiproliferative and antitumor activities demonstrated in preclinical and clinical research.
Purpose of the Study:
- To investigate the impact of thaliblastine on cell cycle progression.
- To evaluate its effects on the O-342 ovarian tumor cell line and its cisplatin-resistant counterpart (O-342/DDP).
Main Methods:
- Flow cytometric analysis was employed to assess cell cycle distribution.
- Ovarian tumor cell lines (O-342 and O-342/DDP) were treated with thaliblastine.
Main Results:
- Thaliblastine induced a comparable cell cycle arrest pattern in both O-342 and O-342/DDP cell lines.
- An initial G2/M phase block was observed within 5 hours of exposure.
- Subsequently, prominent G1 phase arrest occurred, while cells in S-phase completed DNA replication.
Conclusions:
- Thaliblastine effectively modulates cell cycle progression in ovarian cancer cells, including cisplatin-resistant lines.
- The observed G2/M and G1 cell cycle arrest suggests a potential mechanism for its antitumor activity.